Table 3.
Treatments used in the four groups
| Factor | Group | Early-onset | Late-onset | ||||
|---|---|---|---|---|---|---|---|
| MSS (n = 7720) | MSI-H (n = 663) | P value | MSS (n = 37,647) | MSI-H (n = 2377) | P value | ||
| Radiation treatment for stage II-III disease (%) | No radiation given | 767 (20.5) | 69 (19.4) | 0.732 | 6303 (37.3) | 351 (32.2) | 0.009 |
| Neoadjuvant | 2721 (72.7) | 267 (75.0) | 9296 (55.1) | 642 (58.9) | |||
| Adjuvant | 232 (6.2) | 17 (4.8) | 1211 (7.2) | 89 (8.2) | |||
| Neoadjuvant and adjuvant | 19 (0.5) | 2 (0.6) | 61 (0.4) | 6 (0.6) | |||
| Intraoperative | 5 (0.1) | 1 (0.3) | 15 (0.1) | 2 (0.2) | |||
| Median duration of radiation days [IQR] | 38 [0, 41] | 38 [0, 40] | 0.690 | 24 [0, 40] | 31 [0, 40] | 0.097 | |
| Systemic treatment for stage II-III disease (%) | No systemic therapy | 568 (15.3) | 56 (15.5) | 0.309 | 5366 (32.8) | 293 (27.6) | 0.005 |
| Neoadjuvant | 1394 (37.6) | 141 (39.1) | 5915 (36.2) | 424 (40.0) | |||
| Adjuvant | 326 (8.8) | 33 (9.1) | 1531 (9.4) | 115 (10.8) | |||
| Neoadjuvant and adjuvant | 1423 (38.3) | 131 (36.3) | 3534 (21.6) | 228 (21.5) | |||
| Intraoperative | 0 (0.0) | 0 (0.0) | 11 (0.01) | 0 (0.0) | |||
| Type of chemotherapy (%) | No chemotherapy | 4281 (56.5) | 337 (51.9) | 0.153 | 24,237(67.4) | 1483 (65.8) | 0.032 |
| Single agent | 1068 (14.1) | 102 (15.7) | 5268 (14.6) | 378 (16.8) | |||
| Multiagent | 2160 (28.5) | 203 (31.3) | 6093 (16.9) | 376 (16.7) | |||
| Type not documented | 72 (0.9) | 7 (1.1) | 366 (1.0) | 17 (0.8) | |||
| Immunotherapy (%) | Yes | 447 (5.8) | 28 (4.2) | 0.097 | 1314 (3.5) | 67 (2.8) | 0.092 |
| No | 7245 (94.2) | 633 (95.8) | 36,197 (96.5) | 2300 (97.2) | |||
| Median days from diagnosis to surgery [IQR] | 121[42,149] | 124 [47,155] | 0.091 | 97 [23, 144] | 94 [23, 143] | 0.998 | |
| Type of surgery (%) | APR | 865 (15.6) | 87 (18.4) | < 0.001 | 4437 (16.4) | 311 (17.8) | < 0.001 |
| LAR | 3333 (60.3) | 274 (57.9) | 14,983 (55.4) | 929 (53.3) | |||
| Local excision | 477 (8.6) | 25 (5.3) | 4449 (16.4) | 262 (15.0) | |||
| Pelvic exenteration | 152 (2.7) | 21 (4.4) | 604 (2.2) | 54 (3.1) | |||
| Pull through coloanal | 444 (8.0) | 35 (7.4) | 1610 (6.0) | 106 (6.1) | |||
| Total proctocolectomy | 163 (2.9) | 28 (5.9) | 551 (2.0) | 60 (3.4) | |||
| Proctectomy NOS | 45 (0.8) | 1 (0.2) | 139 (0.5) | 10 (0.6) | |||
| Surgery not specified | 49 (0.9) | 2 (0.4) | 278 (1.0) | 12 (0.7) | |||
| Approach (%) | Open | 2026 (40.3) | 209 (47.0) | 0.008 | 9517 (41.2) | 701 (44.8) | 0.014 |
| Laparoscopic | 1934 (38.5) | 164 (36.9) | 9218 (39.9) | 598 (38.3) | |||
| Robotic | 1066 (21.2) | 72 (16.2) | 4340 (18.8) | 264 (16.9) | |||
Bold text in the P value column indicates statistical significance
MSI microsatellite instability, MSS microsatellite stable, IQR interquartile range, LAR low anterior resection, APR abdominoperineal resection